Savara Q3 net loss widens

Savara

12/11/2025 21:16

Overview

Savara reports Q3 net loss of $29.6 mln, compared to $24.2 mln loss last year

Company strengthens balance sheet with $140 mln equity financing

Outlook

Savara strengthens balance sheet to support potential MOLBREEVI launch

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to MOLBREEVI program activities, including regulatory and quality assurance costs

ADMINISTRATIVE COSTS - Significant rise in general and administrative expenses due to strategic personnel additions and commercial activities

BALANCE SHEET STRENGTHENING - $140 mln equity financing enhances financial position for MOLBREEVI commercialization

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.14
Q3 Net Income
-$29.56 mln
Q3 Income from Operations
-$30.26 mln
Q3 Operating Expenses
$30.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Savara Inc is $10.75, about 59.7% above its November 11 closing price of $4.33

Press Release: ID:nBw4lcyh2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)